London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here


Come to London

video-icon

WATCH to find out why


Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

THE EVALUTION OF MACULAR THICKNESS PARAMETERS ON OPTICAL COHERENCE TOMOGRAPHY IN PATIENTS UNDER TOPICAL LATANOPROST AND BIMATOPROST MEDICATIONS

Poster Details

First Author: U.Uzunel TURKEY

Co Author(s):    B. Yuce   D. Aydin   T. Kusbeci   B. Yuksel     

Abstract Details

Purpose:

Prostaglandin (PG) analogues are being widely used to reduce intraocular pressure (IOP) by increasing the uveaoscleral outflow in glaucoma patients. Some authors reported that PG analogues are related with retinal disorders in eyes with blood-ocular barrier injury. We aimed to evaluate and compare the long term changes of macula thickness analysis by OCT in phakic glaucoma patients who use latanoprost and bimatoprost.

Setting:

Izmir Bozyaka Training and Research Hospital, Department of Ophthalmology, TURKEY

Methods:

Twenty eyes of 13 patients who were using 0.005% latanoprost and 21 eyes of 14 patients who were using 0.03% bimatoprost once daily in the evening regimen were included to study. Best corrected visual acuity (BCVA), IOP values, average cube thickness, macular cube volume, central subfield thickness were obtained in the Macula Thickness Analysis mode of Cirrus HD OCT results at the baseline, 6th month and 12th mont visits were recorded.

Results:

IOP was 27.7% lower in latanoprost group and 31.9% lower in bimatoprost group than the baseline at the last visit. Macular thickness of superior 3 mm and nasal 3 mm quadrants and the cube volume decreased significantly in latanoprost group. The central subfield thickness, cube volume and the thickness of each area of the macula and signal strength did not change significantly in bimatoprost group.

Conclusions:

Topical administration of latanoprost and bimatoprost did not induce clinical and structural changes of the macula in glaucoma patients with phakic eyes. Moreover, latanoprost and bimatoprost may be useful in glaucoma patients for lowering IOP effectively without any concern for macular disorders.

Financial Disclosure:

NONE

Back to Poster listing